Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 7/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057336 | 0.87 | SMO (0.48) | PDE1APDE1BPDE1CSMOALDH1A1 | |
| SCHEMBL1062305 | 0.87 | SMO (0.46) | PDE1APDE1BPDE1CSMOALDH1A1 | |
| SCHEMBL12962846 | 0.85 | KMT2A (0.47) | SMOSMN1; SMN2LMNA | |
| SCHEMBL12962853 | 0.83 | SMO (0.42) | SMOALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12962841 | 0.82 | TDP1 (0.45) | SMOALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL10314644 | 0.80 | SMO (0.46) | SMOSMN1; SMN2 | |
| SCHEMBL12962748 | 0.78 | SMO (0.39) | SMOALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL1061404 | 0.78 | SMO (0.53) | SMOALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1060988 | 0.78 | SMO (0.48) | SMOALDH1A1SMN1; SMN2POLB | |
| SCHEMBL1063653 | 0.78 | SMO (0.46) | SMOALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | PDE1A 3767/4885PDE1B 3729/4885PDE1C 4137/4885 |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | PDE1A 3960/4885PDE1B 3894/4885PDE1C 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.